These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37516904)

  • 1. The Relationship Between Naturalistic Psychedelic Use and Clinical Care in Canada.
    Glynos NG; Kruger DJ; Kolbman N; Boehnke K; Lucas P
    J Psychoactive Drugs; 2023; 55(5):660-671. PubMed ID: 37516904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naturalistic Psychedelic Use: A World Apart from Clinical Care.
    Glynos NG; Fields CW; Barron J; Herberholz M; Kruger DJ; Boehnke KF
    J Psychoactive Drugs; 2023; 55(4):379-388. PubMed ID: 35950817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting.
    Argento E; Socias ME; Hayashi K; Choi J; Mackay L; Christie D; Milloy MJ; DeBeck K
    Int J Drug Policy; 2022 Feb; 100():103518. PubMed ID: 34758431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychedelic Experiences and Mindfulness are Associated with Improved Wellbeing.
    Qiu TT; Minda JP
    J Psychoactive Drugs; 2023; 55(2):123-133. PubMed ID: 35438609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychologists' and psychotherapists' knowledge, attitudes, and clinical practices regarding the therapeutic use of psychedelics.
    Kucsera A; Suppes T; Haug NA
    Clin Psychol Psychother; 2023; 30(6):1369-1379. PubMed ID: 37394242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meditation trips: A thematic analysis of the combined naturalistic use of psychedelics with meditation practices.
    Azmoodeh K; Thomas E; Kamboj SK
    Exp Clin Psychopharmacol; 2023 Jun; 31(3):756-767. PubMed ID: 36534415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.
    Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS
    J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An online survey of tobacco smoking cessation associated with naturalistic psychedelic use.
    Johnson MW; Garcia-Romeu A; Johnson PS; Griffiths RR
    J Psychopharmacol; 2017 Jul; 31(7):841-850. PubMed ID: 28095732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers.
    Boehnke KF; Cox K; Weston C; Herberholz M; Glynos N; Kolbman N; Fields CW; Barron J; Kruger DJ
    Front Psychiatry; 2023; 14():1224551. PubMed ID: 37599880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating the associations of acute psychedelic experiences and changes in racial trauma symptoms, psychological flexibility, and substance use among People with Racial and Ethnic Minoritized Identities in the United States and Canada.
    Haeny AM; Lopez JA; Colón Grigas PA; Crouch MC; Davis AK; Williams M
    J Subst Use Addict Treat; 2023 Jun; 149():209035. PubMed ID: 37019336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal associations between psychedelic use and unusual visual experiences in the United States and the United Kingdom.
    Simonsson O; Hendricks PS; Stenfors CU; Goldberg SB; Honk L; Osika W
    J Psychopharmacol; 2024 Jan; 38(1):110-115. PubMed ID: 38140891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deepening our understanding of psychedelics by expanding psychedelic data collection in the United States National Survey on Drug Use and Health.
    Barnett BS
    J Psychopharmacol; 2022 Oct; 36(10):1097-1099. PubMed ID: 36112818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.
    Simonsson O; Goldberg SB
    J Psychoactive Drugs; 2023; 55(1):11-18. PubMed ID: 35000559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of classic psychedelics among adults: a Danish online survey study.
    Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
    Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey.
    Garcia-Romeu A; Davis AK; Erowid E; Erowid F; Griffiths RR; Johnson MW
    Front Psychiatry; 2019; 10():955. PubMed ID: 32038317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between naturalistic use of psychedelics and co-occurring substance use disorders.
    Rabinowitz J; Lev-Ran S; Gross R
    Front Psychiatry; 2022; 13():1066369. PubMed ID: 36704738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.
    Mellner C; Dahlen M; Simonsson O
    Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Assessment of Psychedelic Knowledge Among People Using Psychedelics Naturalistically.
    Kruger DJ; Glynos NG; Fields CW; Herberholz M; Boehnke KF
    J Psychoactive Drugs; 2023; 55(4):420-424. PubMed ID: 36328419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.
    Lea T; Amada N; Jungaberle H; Schecke H; Scherbaum N; Klein M
    Psychopharmacology (Berl); 2020 May; 237(5):1521-1532. PubMed ID: 32043165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.